Five new scientific publications enabled by Attana

Five new scientific articles featuring Attana instruments have recently been published in peer reviewed publications including the highly regarded Science Advances as well as Molecular Cancer Therapeutics, Talanta and Carbohydrate Research.

The team of Professor Roland Kontermann at the Institute of Cell Biology and Immunology, University of Stuttgart, Germany has published their work in the American Association for Cancer Research journal, Molecular Cancer Therapeutics. The article, *Inhibition of Tumor Cell Growth and Cancer Stem Cell Expansion by a Bispecific Antibody Targeting EGFR and HER3* explains their development of a novel bispecific antibody which is shown to suppress the growth of cancer cells in a variety of different models. Additionally, their antibody showed superior performance to the parental antibodies, “holding promise for further preclinical development”.

Other recent Attana enabled scientific articles include:

- *The mechanism of Hsp90-induced oligomerization of Tau* (Science Advances) by Sabrina Weickert et al. at the University of Konstanz, Germany.
- *The impact of structural modification of sulfated polysaccharides on bone morphogenic protein 2 and inhibition of endothelial cell angiogenesis* (Carbohydrate Research) by Ying Wang et al. at the Shanghai Institute of Materia Medica, China.
- *Novel approach to the measurement of antithyroglobulin antibodies in human serum – application of the Quartz Crystal Microbalance sensors* (Talanta) by Lidija S. Vrhovac et al. at the University of Belgrade, Serbia, and
- *Direct attachment of suspension cells to PDA surface and its application in suspension-cell QCM biosensor* (Sensors and Actuators B: Chemical) by Xueming Li et al. at Northwest A&F University, Yangling, China.

Attana congratulates the research teams on their success!

For more information, please contact:
Teodor Aastrup, CEO Attana AB
e-mail: teodor.astrup@attana.com
tel: + 46 8 674 57 00

The Board of Directors for Attana consider that the information in this press release is not likely to have a significant effect on the share price but is of general interest for the shareholders and hence should be communicated.

About Attana

Attana was founded in 2002 with the vision of *in-vitro* characterization of molecular interactions mimicking *in-vivo* conditions. Since then, Attana has developed proprietary label free biosensors for biochemical, crude, sera, and cell-based assays and the Attana Virus Analytics (AVA) platform, a proprietary in-vitro diagnostics (IVD) tool. Attana products and research services are used by Big Pharma, biotech companies and academic institutions within the life sciences. To learn more about our latest services and products, please visit [www.attana.com](http://www.attana.com) or contact sales@attana.com